Success Metrics

Clinical Success Rate
87.2%

Based on 41 completed trials

Completion Rate
87%(41/47)
Active Trials
2(3%)
Results Posted
46%(19 trials)
Terminated
6(10%)

Phase Distribution

Ph phase_4
13
22%
Ph early_phase_1
4
7%
Ph phase_3
6
10%
Ph phase_1
5
9%
Ph not_applicable
8
14%
Ph phase_2
20
34%

Phase Distribution

9

Early Stage

20

Mid Stage

19

Late Stage

Phase Distribution56 total trials
Early Phase 1First-in-human
4(7.1%)
Phase 1Safety & dosage
5(8.9%)
Phase 2Efficacy & side effects
20(35.7%)
Phase 3Large-scale testing
6(10.7%)
Phase 4Post-market surveillance
13(23.2%)
N/ANon-phased studies
8(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.0%

41 of 50 finished

Non-Completion Rate

18.0%

9 ended early

Currently Active

2

trials recruiting

Total Trials

58

all time

Status Distribution
Active(3)
Completed(41)
Terminated(9)
Other(5)

Detailed Status

Completed41
Terminated6
unknown4
Withdrawn3
Enrolling by invitation1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
58
Active
2
Success Rate
87.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (7.1%)
Phase 15 (8.9%)
Phase 220 (35.7%)
Phase 36 (10.7%)
Phase 413 (23.2%)
N/A8 (14.3%)

Trials by Status

enrolling_by_invitation12%
active_not_recruiting12%
completed4171%
unknown47%
withdrawn35%
suspended12%
terminated610%
recruiting12%

Recent Activity

Clinical Trials (58)

Showing 20 of 58 trialsScroll for more
NCT07560878Early Phase 1

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

Recruiting
NCT05975684Phase 3

Baclofen for Children With Rumination Syndrome

Completed
NCT05418049Phase 2

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

Active Not Recruiting
NCT02596763Phase 4

Phone-based Safety Monitoring of Baclofen Prescriptions for Alcohol Use Disorder

Terminated
NCT01604330Phase 2

Baclofen for the Treatment of Alcohol Drinkers

Completed
NCT06840652

Safety & Efficacy of Baclofen for Alcohol Withdrawal in Chronic Liver Disease With Active Alcohol Consumption

Enrolling By Invitation
NCT05161351Phase 4

Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence.

Completed
NCT04471714Phase 2

Effects of Baclofen on Presynaptic Inhibition in Humans

Withdrawn
NCT05877807

Effect of Baclofen to Prevent Post-Traumatic Stress Disorder

Completed
NCT00647738Phase 1

Comparative Bioavailability Study of Baclofen 20 mg Tablets in Healthy Male Volunteers / Fasting State

Completed
NCT06175507Not Applicable

Efficacy of Baclofen Vs Naltrexon in Achieving & Maintaining Abstinence in Alcohol Dependence.

Unknown
NCT04509336Not Applicable

Orphenadrine Versus Baclofen in Treatment of Muscle Cramps in Cirrhotic Patients

Terminated
NCT01743651Phase 3

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Completed
NCT02998151Early Phase 1

Neurophysiological and Acute Pharmacological Studies in FXS Patients

Completed
NCT03860662Phase 4

The Effect of Oral Baclofen and Botulinum Toxin Treatments in Hemiplegic Spasticity on the Nociceptive Flexor Reflex

Completed
NCT02462317Phase 4

Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment

Completed
NCT03034408Phase 2

Nalmefene, Baclofen and Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects

Completed
NCT03068897Phase 4

Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain

Completed
NCT02723383Phase 3

Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU

Completed
NCT01265550Phase 3

A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors

Completed

Drug Details

Intervention Type
DRUG
Total Trials
58